Who Paid My Doc
Caitlin Elgarten
Pediatric Hematology-Oncology Philadelphia, PA Medical Doctor
NPI 1760776991 CMS profile 868765
3500 Civic Center Blvd, Philadelphia, PA 19104
General payments
$9,275
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$216,850
Through program year 2025, Caitlin Elgarten of Philadelphia, PA is reported in the CMS Open Payments database as having received $9,275 across 13 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $216,850 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 76th percentile of Pediatric Hematology-Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $9,001 | 9 | |
| 2024 | General | $151 | 2 | |
| 2023 | General | $31 | 1 | |
| 2022 | General | $91 | 1 |
Beside peers
- Caitlin Elgarten
- Pediatric Hematology-Oncology median
- Middle half of Pediatric Hematology-Oncology
- National median
In program year 2025, general payments to Caitlin Elgarten were reported at $9,001. Among 1,352 Pediatric Hematology-Oncology profiles paid that year, the median was $204 and the middle half received between $80 and $2,819.
Show as a table
| Year | Caitlin Elgarten | Pediatric Hematology-Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $184 | $69–$2,094 | $163 |
| 2020 | $0 | $220 | $37–$3,941 | $114 |
| 2021 | $0 | $366 | $63–$4,909 | $132 |
| 2022 | $91 | $181 | $66–$2,775 | $149 |
| 2023 | $31 | $175 | $62–$2,600 | $160 |
| 2024 | $151 | $227 | $66–$2,992 | $164 |
| 2025 | $9,001 | $204 | $80–$2,819 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
13 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Hematology-Oncology in Pennsylvania
Stephan Grupp
Pediatric Hematology-Oncology · Philadelphia, PA
Samuel Blackman
Pediatric Hematology-Oncology · Philadelphia, PA
Giselle Saulnier- Sholler
Pediatric Hematology-Oncology · Hershey, PA
Jonathan Bernstein
Pediatric Hematology-Oncology · Hershey, PA
Benjamin Samelson Jones
Pediatric Hematology-Oncology · Philadephia, PA
Frederico Xavier
Pediatric Hematology-Oncology · Pittsburgh, PA
Related records
Pediatric Hematology-Oncology in Pennsylvania
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Hematology-Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Pennsylvania
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.